Back to Trials
NCT05386615Recruiting

Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids

InSightec

Start Date

2/16/2016

Completion Date

12/31/2026

Summary

The goal of this Registry Study is to capture clinical pregnancy outcomes and fibroid treatment background data for any subject post-Exablate treatment for their symptomatic fibroids.

Detailed Description

This is an observational study only for all consented subjects who undergo an Exablate treatment. The Exablate procedure is a commercial treatment. The objective of this registry is to collect data about the effect of Exablate treatment on potential pregnancy occurrences in this population for two years post-treatment for purposes of labeling updates and overall safety data collection.

Eligibility Criteria

Age Range: 18 years to 50 years

Inclusion Criteria: - - Eligibility is as per the symptomatic fibroids device indication. - All registry-consented patients following the treatment of their fibroid(s) with the Exablate system. Exclusion Criteria: -

Interventions

DEVICE

Body System - Functional

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Uterine Fibroid

Locations

UCLA

Los Angeles, California 90095

United States

Stanford University

Stanford, California 94305

United States

Mayo Clinic

Rochester, Minnesota 55905

United States

Huashan Hospital Affiliated to Fudan University

Shanghai,

China

Shanghai No. 1 Hospital

Shanghai,

China

Shanghai No.1 Hospital

Shanghai,

China